OSLO, Norway, Aug. 27, 2025 /PRNewswire/ -- Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment. Highlights for the first half of 2025: Radspherin® Positive final data from Phase1/2a...
Hence then, the article about oncoinvent asa half yearly report strong focus on financial discipline and advancing phase 2 program in ovarian cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer )
Also on site :
- UK to list 65-year-olds as reservists amid Russia threat claims – Telegraph
- Scott Ritter say he was ‘de-banked’
- AI boom fuels fears of an industry bubble (VIDEO)